Radiopharm Theranostics Limited Depositary Receipt
Radiopharm Theranostics Limited Depositary Receipt is the U.S.-traded depositary receipt for Radiopharm Theranostics Limited, a clinical-stage biopharmaceutical company focused on radiopharmaceutical products for diagnostic imaging and targeted therapy. The company develops oncology-focused technologies designed to address areas of high unmet medical need, with programs spanning both pre-clinical and clinical stages of development. Its current pipeline includes diagnostic and therapeutic candidates built around radiopharmaceutical platforms for cancer targeting, reflecting a business centered on precision medicine and molecular imaging. Radiopharm Theranostics Limited serves researchers, clinicians, and healthcare stakeholders working in cancer diagnosis and treatment, and its depositary receipt provides a market-facing representation of the company’s ordinary shares for international investors.
$1.03
-$0.05 (-4.63%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-953.39% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 1114.3% YoY with margins expanding 11469.9pp.
Negative free cash flow of -A$37M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
A$4M
▲ +1114.3% YoY
Net Income (TTM)
-A$38M
▲ +20.0% YoY
Op. Margin
-953.39%
▲ +11469.9pp YoY
ROIC
-77.94%
▲ +2.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-A$37M
▼ -59.5% YoY
Op. Cash Flow (TTM)
-A$37M
▼ -59.5% YoY
Net Debt
-A$29M
Net Cash Position
Cash & Equiv.
A$29M
3Y CAGR: +752.0%
Continue Research
Is Radiopharm Theranostics Limited Depositary Receipt (RADX) overvalued?
Radiopharm Theranostics Limited Depositary Receipt (RADX)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Radiopharm Theranostics Limited Depositary Receipt scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Radiopharm Theranostics Limited Depositary Receipt a high-quality business?+
Radiopharm Theranostics Limited Depositary Receipt scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -953.4% operating margin and a -77.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Radiopharm Theranostics Limited Depositary Receipt a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh RADX's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.